ClinicalTrials.gg
CompletedNCT04811027TACTI-003Updated Dec 11, 2025

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

A Phase 2 interventional study of eftilagimod alpha and pembrolizumab (KEYTRUDA®) in HNSCC, sponsored by Immutep S.A.S.. Completed at 28 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Immutep S.A.S. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain — 36 open to participants now, 70 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Spain.

Enrollment
75th of 161
171 · median 160
Started
2021
with 21 others
Phase 2
41 of 167
3 open now
Registered
93rd of 167
by date

Among the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, this one is the 75th largest by enrollment of the 161 interventional ones that give a count, is one of 22 that started in 2021, is one of 41 in phase 2, and was the 93rd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

36 of the 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Squamous Cell Carcinoma of Head and Neck with a site in Spain, or all of them as a file.
02

Study summary

Evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with programmed death-ligand 1 (PD-L1) positive (combined positive score [CPS] ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors.

Read the detailed description

Up to 154 patients will be recruited in the TACTI-003 (Two ACTive Immunotherapies) Phase IIb study which will take place across several countries in Australia, Europe and United States of America in up to 35 experienced clinical sites. It will evaluate the safety and efficacy of eftilagimod alpha in combination with pembrolizumab against pembrolizumab alone in 1st line metastatic or recurrent HNSCC with PD-L1 positive (CPS ≥1) tumors, and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors. Subjects in cohort A (CPS ≥1) will be randomized 1:1 to receive either "P+E": efti plus pembrolizumab or "P only": pembrolizumab alone. Subjects in cohort B (CPS \<1) will receive a combination of efti and pembrolizumab "P+E". Efti will be administered for up to 24 months using a 30 mg subcutaneous dosing every 2 or 3 weeks. Pembrolizumab will be administered for up to 24 months using a 400 mg intravenous (30 min) dosing every 6 weeks.

03

Conditions studied

  • HNSCC

Keywords

  • HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. - or cytologically-confirmed recurrent disease not amenable to curative treatment with local or systemic therapy, or (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx that is considered incurable by local therapies and to be treated in the palliative setting and who are PD-X naïve.
  2. Availability of tissue for biomarker analysis from a core or excisional .
  3. Availability of PD-L1 biomarker result by using the FDA approved Dako standardized diagnostic test (PD-L1 IHC 22C3 pharmDx).
  4. Availability of tissue for testing of human papillomavirus (HPV) status for oropharyngeal cancer (p16 expression testing).
  5. (ECOG) performance status 0-1.

Main Exclusion Criteria:

  1. Disease is suitable for local therapy administered with curative intent.
  2. Previously treated with ≥ 1 systemic regimen for recurrent and/or metastatic disease (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally or locoregionally advanced disease).
  3. Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including subjects with HNSCC of unknown primary, squamous cell carcinoma originating from skin, or non-squamous histologies (e.g. nasopharynx, salivary gland or mucosal melanoma).
  4. Has progressive disease (PD) within 6 months of completion of curatively intended systemic treatment for locally or locoregionally advanced HNSCC, or requires chemotherapy based therapeutic regimen due to e.g., rapidly progressing disease or need of aggressive sympton control.
  5. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  6. Has received prior chemotherapy, anti-cancer monoclonal antibody, major surgery, another systemic cancer therapy or has participated in a trial of an agent or has used an investigational device within 4 weeks prior to cycle 1 day 1.
  7. Known active central nervous system metastasis and/or carcinomatous meningitis. Subjects with previously treated may participate provided they are radiologically stable: i.e. without evidence of progression documented by repeat imaging performed after therapy completed for CNS metastasis and with at least 4 weeks difference, clinically stable and without requirement for treatment for at least 14 days prior to cycle 1 day 1.
  8. Receives continuous systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other medications within 7 days prior to cycle 1 day 1. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    (CPS ≥1): pembrolizumab (KEYTRUDA®) + efti

    eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles (1 cycle = 6 weeks). pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).

    Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)

  • Active comparator
    (CPS ≥1): pembrolizumab (KEYTRUDA®)

    pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).

    Drug: pembrolizumab (KEYTRUDA®)

  • Experimental
    (CPS <1): pembrolizumab (KEYTRUDA®) + efti

    eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles (1 cycle = 6 weeks). pembrolizumab (KEYTRUDA®): 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).

    Drug: eftilagimod alpha · Drug: pembrolizumab (KEYTRUDA®)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: Up to 24 months

Secondary outcomes

  1. Overall survival (OS)

    Time frame: Up to 24 months

  2. Objective response rate (ORR) according to iRECIST

    Time frame: Up to 24 months

  3. Duration of responses according to iRECIST and RECIST 1.1

    Time frame: Up to 24 months

  4. Disease control rate according to iRECIST and RECIST 1.1

    Time frame: Up to 24 months

  5. Progression free survival (PFS) according to iRECIST and RECIST 1.1

    Time frame: Up to 24 months

  6. Frequency of (serious) adverse events

    Time frame: Up to 24 months

  7. Severity of (serious) adverse events according to the United States National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v5.0

    Time frame: Up to 24 months

07

Study locations

28 sites
  • University of Alabama at Birmingham (UAB) - O'Neal Cancer Center
    Birmingham, Alabama 35249, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Oncology Consultants
    Houston, Texas 77030, United States
  • Macquarie University Hospital
    Macquarie Park, New South Wales 2109, Australia
  • AZ Sint-Jan Brugge
    Bruges, 8000, Belgium
  • Antwerp University Hospital
    Edegem, 2650, Belgium
  • Centre Hospitalier Universitaire (CHU) de Liege
    Liège, 4000, Belgium
  • AZ Nikolaas
    Sint-Niklaas, 9100, Belgium
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Herlev Hospital
    Herlev, 2700, Denmark
  • Universitätsklinikum Bonn
    Bonn, North Rhine-Westphalia 53127, Germany
  • University Hospital Essen
    Essen, 45147, Germany
  • Nationales Centrum für Tumorerkrankungen Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum Ulm
    Ulm, 89075, Germany
  • The Oncology Institute "Prof Dr Ion Chiricuta" I.O.C.N.
    Cluj-Napoca, 400015, Romania
  • Vall d'Hebron Institute of Oncology (VHIO)
    Barcelona, 08035, Spain
  • Hospital de la Santa Creu i de Sant Pau
    Barcelona, 08041, Spain
  • Institut Català d'Oncologia - Hospital Universitari de Girona
    Girona, 17007, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • START Madrid (Hospital Universitario Fundación Jiménez Díaz)
    Madrid, 28040, Spain
  • Hospital 12 Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Arensia Exploratory Medicine Llc
    Kapitanivka, AL 08112, Ukraine
  • Institute of Cancer Science - Beatson West of Scotland Cancer Centre
    Glasgow, 1053, United Kingdom
  • University College London Hospitals NHS Foundation - The Harley Street Clinic
    London, NW1 2PG, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Nottingham University Hospitals, NHS Trust
    Nottingham, NG5 1PB, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2024, 30 months.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 30 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 23, 2021
StartActual
Aug 27, 2021
Primary completionActual
Mar 11, 2024
CompletionActual
Nov 5, 2025
Results delay requested
Feb 24, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04811027
Lead sponsor
Immutep S.A.S.
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Aug 27, 2021
Primary completion
Mar 11, 2024
Completion
Nov 5, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etilagimod alpha

Start the discussion